
Folks who take the blockbuster weight-loss med tirzepatide (Zepbound) may regain much of the weight they lost soon after discontinuing it, new research shows. A trial funded by Eli Lilly, the injected drug’s maker, found that “in patients with obesity or overweight, withdrawing tirzepatide led to substantial regain of weight.” On the other hand, continuing on with tirzepatide kept the weight off, over the full two years of the trial. Of course, sticking with drug could mean big bills for users. Medicare and Medicaid do not cover the drug, and if your private insurance doesn’t cover Zepbound, it can cost over $1,000 per month. Lilly says certain commercial card savings programs it offers can reduce the monthly cost to about $550, or even lower, however. Zepbound was approved for weight loss by the U.S. Food and Drug Administration on Nov. 8, and Lilly announced its availability to consumers on Dec. 6. To trigger weight loss, tirzepatide mimics two hormones, GLP-1 and GIP, which stimulate the release of insulin in the body. It quells appetite and slows the rate at which food moves through the stomach, helping patients feel full. It’s the first drug in its class to compete with another weight-loss blockbuster, Wegovy. Wegovy, made by Novo Nordisk, uses a similar active ingredient, semaglutide, which only focuses on GLP-1. That difference appears to translate to… read on > read on >